Literature DB >> 19403940

Hypertension as a surrogate marker for the activity of anti-VEGF agents.

O Mir, S Ropert, J Alexandre, F Goldwasser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19403940     DOI： 10.1093/annonc/mdp206

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  16 in total

Review 1.  Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.

Authors:  Ryan D Gentzler; Sarah E Yentz; Jyoti D Patel
Journal:  Curr Treat Options Oncol       Date:  2013-12

2.  Treatment of bevacizumab-induced hypertension by amlodipine.

Authors:  Olivier Mir; Romain Coriat; Stanislas Ropert; Laure Cabanes; Benoit Blanchet; Sandra Camps; Bertrand Billemont; Bertrand Knebelmann; François Goldwasser
Journal:  Invest New Drugs       Date:  2010-09-29       Impact factor: 3.850

3.  Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome.

Authors:  A Wick; N Schäfer; N Dörner; D Schemmer; M Platten; M Bendszus; W Wick
Journal:  J Neurooncol       Date:  2009-08-29       Impact factor: 4.130

4.  Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.

Authors:  Sarah B Sunshine; Susan M Dallabrida; Ellen Durand; Nesreen S Ismail; Lauren Bazinet; Amy E Birsner; Regina Sohn; Sadakatsu Ikeda; William T Pu; Matthew H Kulke; Kashi Javaherian; David Zurakowski; Judah M Folkman; Maria Rupnick
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

Review 5.  Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.

Authors:  Dorothy Keefe; Joanne Bowen; Rachel Gibson; Thean Tan; Meena Okera; Andrea Stringer
Journal:  Oncologist       Date:  2011-03-25

Review 6.  Tumor control versus adverse events with targeted anticancer therapies.

Authors:  Dorothy M K Keefe; Emma H Bateman
Journal:  Nat Rev Clin Oncol       Date:  2011-12-20       Impact factor: 66.675

Review 7.  Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

8.  An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.

Authors:  Olivier Mir; Romain Coriat; Laure Cabanes; Stanislas Ropert; Bertrand Billemont; Jérôme Alexandre; Jean-Philippe Durand; Jean-Marc Treluyer; Bertrand Knebelmann; François Goldwasser
Journal:  Oncologist       Date:  2011-08-01

9.  Leptomeningeal metastases in breast cancer.

Authors:  Brian J Scott; Santosh Kesari
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

Review 10.  Targeting angiogenesis: progress with anti-VEGF treatment with large molecules.

Authors:  Axel Grothey; Evanthia Galanis
Journal:  Nat Rev Clin Oncol       Date:  2009-07-28       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.